BioSpace News Archive

iTolerance, Inc., a biotechnology company focused on the development of innovative regenerative medicines, announced that Dr. Anthony Japour, Chief Executive Officer of iTolerance, will participate at the Virtual Investor Ask the CEO Conference on Wednesday, October 25, 2023 at 1:00 PM ET.

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it will report financial results for the third quarter 2023 after market close on Thursday, November 2, 2023.

AbCellera (Nasdaq: ABCL) will announce its third quarter 2023 financial results on Thursday, November 2, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2023 after the market close on Wednesday November 8th, 2023.

Paradigm-shifting neuromodulation company, StimAire, has completed its first clinical trial in Australia.

Indivior PLC (LSE/Nasdaq: INDV) today announced that it has gained exclusive global rights to develop, manufacture, and commercialize Alar Pharmaceuticals Inc.'s (“Alar”) portfolio of long-acting injectable formulations that release a prodrug1 of buprenorphine at varying durations, including its lead long-acting injectable (“LAI”) candidate, ALA-1000.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces that it will host a virtual KOL event on Bria-IMT™ potential in advanced metastatic breast cancer on Thursday, October 26, 2023 at 10:00am ET.

Immunis, Inc. is delighted to announce that its Chief Business Officer, Mark Cabato, will be a keynote speaker at this year’s Drug Discovery Strategic Summit. Mark is set to delve deeper into Immunis’ cutting-edge cellular secretome technology, which has shown pre-clinical efficacy in improving muscle regeneration and functio

Ontada ® was awarded a competitive contract with the U.S. Food and Drug Administration (FDA) to advance the use of real-world data (RWD) in the U.S. community oncology setting.

Melinta Therapeutics, LLC announced today, the presentation of nine scientific presentations with data from its current anti-infective portfolio at Infectious Disease Week (IDWeek) 2023, taking place October 11-15, 2023, in Boston, MA.